Double-Dose HIV drug shows promise for Co-Infected patients
NCT ID NCT05630872
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study tested whether taking a double dose of the HIV drug dolutegravir (50 mg twice daily) along with the TB drug rifapentine can keep HIV under control in people with both HIV and tuberculosis. Thirty adults participated. The goal was to see if the higher dose is safe and effective enough to prevent the HIV virus from rebounding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Durban International CRS (Site # 11201)
Wentworth, Durban, 4052, South Africa
-
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793)
Worcester, Western Cape, 6850, South Africa
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802)
Bangkok, 10330, Thailand
-
University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792)
Mowbray, Cape Town, Western Cape, 7700, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a new patient cohort unlock the secrets of TB treatment success?
- Shorter TB treatment: a 4-Month regimen put to the test
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Lung damage after TB: a new study tests whether rehabilitation can restore breathing and quality of life